Sarcopenia is the age-related loss of muscle mass and strength. Some of the common causes of sarcopenia include aging, malnutrition, physical inactivity, chronic diseases and neurological disorders. The increasing prevalence of sarcopenia owing to rising geriatric population has boosted the demand for sarcopenia treatment drugs and products in recent years. The global Sarcopenia Treatment market houses various drugs and nutritional supplements that help in improving muscle strength and physical performance. The availability of nutritional supplements containing proteins, vitamins, minerals and amino acids play a vital role in muscle mass and strength gain.

The global Sarcopenia Treatment Market is estimated to be valued at US$ 3.01 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Key Trends:
The rising geriatric population, increasing life expectancy and growing prevalence of chronic diseases are some of the key factors fueling the growth of the sarcopenia treatment market. As per the UN estimates, the world's population aged 60 years and above is projected to reach 2.1 billion by 2050. Physiological factors like aging result in reduced generation of new muscle fibers and increased muscle wasting. Further, increasing adoption of sedentary lifestyles contribute significantly to loss of muscle mass and strength. The market players are increasingly focusing on developing new drugs, nutritional supplements and therapeutic biomolecules to effectively target sarcopenia treatment. They are also investing in clinical trials to evaluate efficacy and safety of potential treatment options. The availability of advanced treatment regimens is expected to further accelerate the sarcopenia treatment market growth during the forecast period.

Segment Analysis
Vitamins and mineral supplements are expected to dominate the sarcopenia treatment market during the forecast period. This segment holds the largest share of the market currently due to rise in preference for nutritional supplements over drugs to treat sarcopenia. The tolerability and safety profile of vitamins and minerals make them a preferred choice among the aging population for sarcopenia treatment.

Key Takeaways
The global Sarcopenia Treatment Market Share is expected to witness high growth. The North America region currently dominates the sarcopenia treatment market and is expected to continue its dominance during the forecast period. This is attributed to rising geriatric population and greater availability of advanced treatment options in the region. Asia Pacific region is expected to witness fastest growth during the forecast period owing to growing aging population and rising healthcare expenditure in key countries like China, Japan, and Australia in the region.

Key players related content comprises Key players operating in the sarcopenia treatment market are Abbott Laboratories, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., and GlaxoSmithKline plc. Abbott Laboratories holds a major share of the vitamins and mineral supplements segment. Novartis AG offers prescription drugs for sarcopenia treatment in collaboration with other players.

For more insights, read- https://www.ukwebwire.com/sarcopenia-treatment-market-trends-size-and-share-analysis/